Abstract
Neisseria meningitidis may be classified according to the lipooligosaccharide immunotype. We show that this classification can be achieved by PCR genotyping of the genes involved in the lipooligosaccharide inner-core biosynthesis, lpt3, lpt6, lgtG and lot3. Genotyping data correlated well (90-100%) with mass spectrometry data and was, therefore, applied to screen a random subset of recent N. meningitidis serogroup B isolates from Europe. Analysis of the proportion of the different lipooligosaccharide types highlighted the predominance of L3 strains. Surprisingly, high rates of L2 type strains were found in Spain (17%, versus 2.5% in Germany and 1.9% in the United Kingdom). Therefore, we also investigated further these Spanish L2 strains in an attempt to explain such prevalence despite the known sensitivity of L2 immunotype to complement. We explored the hypothesis that these strains express high amounts of factor H-binding protein (fHbp), but we found, on the contrary, that L2 strains express low or undetectable amounts of fHbp. Our findings suggest that, in addition to a genetic analysis, a multivalent approach may be necessary to estimate the effectiveness of a N. meningitidis serogroup B vaccine.
References
Sep 1, 1992·Microbial Pathogenesis·D M JonesJ T Poolman
Dec 1, 1988·Journal of General Microbiology·C A NairnH Smith
Oct 1, 1994·Journal of Medical Microbiology·R J ScholtenJ T Poolman
Sep 29, 1999·Vaccine·J J DrabickW D Zollinger
Jun 11, 2002·Microbiology·Peixuan ZhuChao-Ming Tsai
Nov 22, 2002·FEMS Immunology and Medical Microbiology·A W BerringtonM P Jennings
Mar 19, 2003·The Journal of Experimental Medicine·Vega MasignaniMariagrazia Pizza
Oct 4, 2003·The Journal of Biological Chemistry·Sanjay RamPeter A Rice
Dec 23, 2003·Infection and Immunity·Margaret Anne J GidneyJames C Richards
Mar 25, 2004·Infection and Immunity·Leah D FletcherGary W Zlotnick
Mar 26, 2004·Vaccine·Jan M BraunDonald M Weir
Oct 7, 2004·Journal of Bacteriology·J Claire WrightE Richard Moxon
Dec 3, 2005·Vaccine·Susanne JacobssonPer Olcén
May 12, 2006·The Journal of Biological Chemistry·Charlene M KahlerDavid S Stephens
Jul 11, 2006·Clinical and Vaccine Immunology : CVI·Peter T BeerninkDan M Granoff
Nov 15, 2006·Infection and Immunity·Michele M EstabrookJ McLeod Griffiss
Dec 16, 2006·FEMS Microbiology Reviews·Keith A JolleyMartin C J Maiden
May 28, 2008·The Journal of Experimental Medicine·Maria Jose UriaChristoph M Tang
Sep 23, 2008·Carbohydrate Research·Biswa ChoudhuryRussell W Carlson
Mar 18, 2009·Infection and Immunity·V WeynantsJan T Poolman
May 12, 2009·Vaccine·Stefania BambiniMaurizio Comanducci
Aug 12, 2009·Glycobiology·Frank St MichaelAndrew D Cox
Jan 2, 2010·Vaccine·Rolando PajonDan M Granoff
Mar 12, 2010·Expert Review of Vaccines·Ameneh Khatami, Andrew J Pollard
Jul 14, 2010·Vaccine·Han-Qing JiangAnnaliesa S Anderson
Apr 22, 2011·Clinical and Vaccine Immunology : CVI·Jay LucidarmeChristoph M Tang
Nov 5, 2011·Molecular Microbiology·Natalie J GriffithsMumtaz Virji